PG545

DRUG2 trials

Sponsors

Zucero Pty Ltd

Conditions

Advanced Solid Tumours

Phase 1

Study of the Safety and Tolerability of PG545 in Patients With Advanced Solid Tumours

TerminatedNCT01252095

Zucero Pty LtdAdvanced Solid Tumours

Start: 2011-01-31End: 2011-10-31Updated: 2017-10-09

Study of the Safety and Tolerability of IV Infused PG545 in Patients With Advanced Solid Tumours

CompletedNCT02042781

Zucero Pty LtdAdvanced Solid Tumours

Start: 2014-01-31End: 2016-09-30Updated: 2017-10-09

Related Papers

Immunomodulatory activities of pixatimod: emerging nonclinical and clinical data, and its potential utility in combination with PD-1 inhibitors

Journal for ImmunoTherapy of Cancer2018-06-1449 citations

An open-label, multi-center phase I study of the safety and tolerability of the novel immunomodulatory agent PG545 in subjects with advanced solid tumors.

Journal of Clinical Oncology2017-05-2010 citations